Compare Summit Therapeutics Inc (SMMT) vs Advanced Drainage Systems Inc (WMS) Price & Performance

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, while P/B stands at 22.19. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancer, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.18 suggesting 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish with 61% buy ratings, but the stock remains speculative due to its pre-revenue status and dependence on a single drug candidate.

WMS trades at $133.67, down 1.54% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin. Recent news highlights institutional buying and positive analyst coverage, though technical indicators show near-term pressure.

The outlook is mixed: analyst consensus targets $191.50, implying upside, but near-term technical weakness and a projected net cash outflow in 2026 pose risks. Investment appeal hinges on execution of growth initiatives and margin stability amid competitive and macroeconomic headwinds.